326 related articles for article (PubMed ID: 27746224)
1. Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial.
Victor JC; Lewis KD; Diallo A; Niang MN; Diarra B; Dia N; Ortiz JR; Widdowson MA; Feser J; Hoagland R; Emery SL; Lafond KE; Neuzil KM
Lancet Glob Health; 2016 Dec; 4(12):e955-e965. PubMed ID: 27746224
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial.
Brooks WA; Zaman K; Lewis KD; Ortiz JR; Goswami D; Feser J; Sharmeen AT; Nahar K; Rahman M; Rahman MZ; Barin B; Yunus M; Fry AM; Bresee J; Azim T; Neuzil KM
Lancet Glob Health; 2016 Dec; 4(12):e946-e954. PubMed ID: 27746226
[TBL] [Abstract][Full Text] [Related]
3. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.
Ortiz JR; Goswami D; Lewis KD; Sharmeen AT; Ahmed M; Rahman M; Rahman MZ; Feser J; Neuzil KM; Brooks WA
Vaccine; 2015 Jun; 33(29):3415-21. PubMed ID: 25917680
[TBL] [Abstract][Full Text] [Related]
4. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.
Tapia MD; Sow SO; Tamboura B; Tégueté I; Pasetti MF; Kodio M; Onwuchekwa U; Tennant SM; Blackwelder WC; Coulibaly F; Traoré A; Keita AM; Haidara FC; Diallo F; Doumbia M; Sanogo D; DeMatt E; Schluterman NH; Buchwald A; Kotloff KL; Chen WH; Orenstein EW; Orenstein LAV; Villanueva J; Bresee J; Treanor J; Levine MM
Lancet Infect Dis; 2016 Sep; 16(9):1026-1035. PubMed ID: 27261067
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD;
Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
Vesikari T; Karvonen A; Smith HM; Dunning A; Razmpour A; Saville MK; Gruber WC; Forrest BD
Pediatrics; 2008 Mar; 121(3):e568-73. PubMed ID: 18299305
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.
Nichol KL; Mendelman PM; Mallon KP; Jackson LA; Gorse GJ; Belshe RB; Glezen WP; Wittes J
JAMA; 1999 Jul; 282(2):137-44. PubMed ID: 10411194
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Seasonal Influenza Vaccination in Children in Senegal During a Year of Vaccine Mismatch: A Cluster-randomized Trial.
Diallo A; Diop OM; Diop D; Niang MN; Sugimoto JD; Ortiz JR; Faye EHA; Diarra B; Goudiaby D; Lewis KDC; Emery SL; Zangeneh SZ; Lafond KE; Sokhna C; Halloran ME; Widdowson MA; Neuzil KM; Victor JC
Clin Infect Dis; 2019 Oct; 69(10):1780-1788. PubMed ID: 30689757
[TBL] [Abstract][Full Text] [Related]
10. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
[TBL] [Abstract][Full Text] [Related]
11. Live attenuated versus inactivated influenza vaccine in infants and young children.
Belshe RB; Edwards KM; Vesikari T; Black SV; Walker RE; Hultquist M; Kemble G; Connor EM;
N Engl J Med; 2007 Feb; 356(7):685-96. PubMed ID: 17301299
[TBL] [Abstract][Full Text] [Related]
12. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly.
Treanor JJ; Mattison HR; Dumyati G; Yinnon A; Erb S; O'Brien D; Dolin R; Betts RF
Ann Intern Med; 1992 Oct; 117(8):625-33. PubMed ID: 1530193
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years.
Block SL; Toback SL; Yi T; Ambrose CS
Clin Ther; 2009 Oct; 31(10):2140-7. PubMed ID: 19922885
[TBL] [Abstract][Full Text] [Related]
14. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
[TBL] [Abstract][Full Text] [Related]
15. Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial.
Steinhoff MC; Katz J; Englund JA; Khatry SK; Shrestha L; Kuypers J; Stewart L; Mullany LC; Chu HY; LeClerq SC; Kozuki N; McNeal M; Reedy AM; Tielsch JM
Lancet Infect Dis; 2017 Sep; 17(9):981-989. PubMed ID: 28522338
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
[TBL] [Abstract][Full Text] [Related]
17. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
Belshe RB; Gruber WC; Mendelman PM; Cho I; Reisinger K; Block SL; Wittes J; Iacuzio D; Piedra P; Treanor J; King J; Kotloff K; Bernstein DI; Hayden FG; Zangwill K; Yan L; Wolff M
J Pediatr; 2000 Feb; 136(2):168-75. PubMed ID: 10657821
[TBL] [Abstract][Full Text] [Related]
19. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J;
Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a live attenuated influenza vaccine in Chinese healthy children aged 3-17 years in one study center of a randomized, double-blind, placebo-controlled phase 3 clinical trial, 2016/17 season.
Wang S; Zheng Y; Jin X; Gan Z; Shao Y; Zhu C; Hu X; Liang Z; Chen Y; Xing B; Lv H; Xu N
Vaccine; 2020 Aug; 38(38):5979-5986. PubMed ID: 32747213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
